Dynavax Technologies Corporation (DVAX)

Currency in USD
11.180
+0.380(+3.52%)
Closed·
10.960-0.220(-1.97%)
·

DVAX Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
0.21 / 0.13
Revenue / Forecast
94.90M / 94.41M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2025--/0.05--/77.35M----Free Sign Up
09/20250.21/0.1394.9M/94.41M+61.54%+0.52%Free Sign Up
06/20250.14/0.195.44M/85.57M+40%+11.53%Free Sign Up
03/2025-0.77/0.0468.16M/67.86M-2,025%+0.44%Free Sign Up
12/20240.05/0.0471.1M/72.44M+25%-1.85%Free Sign Up
09/20240.12/0.1280.63M/85.06M0%-5.21%Free Sign Up
06/20240.08/0.0673.8M/76.04M+33.33%-2.95%Free Sign Up
03/2024-0.07/-0.0250.79M/55.68M-250%-8.78%Free Sign Up
12/2023--/-0.0355.59M/52.4M+100%+6.09%Free Sign Up
09/20230.1/-0.0469.51M/60.3M+350%+15.27%Free Sign Up

All numbers in USD

Dynavax Technologies Corporation Earnings Call Summary for Q3/2025

  • Dynavax reported Q3 2025 EPS of $0.21, exceeding forecasts by 61.54%, with revenue reaching $94.9 million, up 18% year-over-year, driving a 2.49% stock increase in aftermarket trading.
  • Flagship product Heplisav-B captured 46% market share, with significant retail sector gains, contributing to net product revenue of $90 million, a 13% increase from Q3 2024.
  • GAAP net income rose to $27 million from $18 million in Q3 2024, while non-GAAP adjusted EBITDA reached $36 million, up from $25 million last year.
  • Management raised full-year 2025 adjusted EBITDA guidance to at least $80 million and projected Heplisav-B revenue between $315-325 million by year-end.
  • CEO Ryan Spencer highlighted upcoming pipeline milestones in H2 2026, including potential expansions in COVID-19 and shingles vaccine programs with opportunities for strategic partnerships.
Last Updated: 05/11/2025, 23:24
Read Full Transcript

FAQ

What Is Dynavax's Earnings Per Share (TTM)?

The Dynavax EPS (TTM) is -0.36.

When Is The Next Dynavax Earnings Date?

Dynavax will release its next earnings report on 18 Feb 2026.

What Is Dynavax’s Revenue Forecasts For Upcoming Quarters?

Dynavax’s revenue forecast is 77.35M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.